| Clinical Trial on the Protective Role of Vitamin B3 in Enhancing Immunotherapy for Bladder Cancer Patients (NCT07119996) | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 2025-08-01 |
| Study of GS-4321 in Healthy Participants and Participants With Chronic Hepatitis Delta Virus (NCT07096193) | Gilead Sciences | 2025-07-31 |
| Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of DAT-1604 in Advanced Solid Tumor (NCT06998173) | Danatlas Pharmaceuticals Co., Ltd | 2025-07-31 |
| A Clinical Study Evaluating the Dermal Safety of Soluble Denosumab Microneedle Patches (NCT07085520) | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 2025-07-31 |
| A Clinical Study of GO306 in Patients With Advanced Solid Tumors (NCT07128914) | GeneSail Biotech (Shanghai) Co., Ltd. | 2025-07-31 |
| Exploratory Study of Super DC Cell Injection in Preventing Recurrence After Radical Surgery for Tumors (NCT07146672) | Shanghai Cell Therapy Group Co.,Ltd | 2025-07-31 |
| A Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of BBM-D101 in the Treatment of Duchenne Muscular Dystrophy. (NCT07058662) | Belief BioMed (Beijing) Co., Ltd | 2025-07-31 |
| A Phase I Study Investigating the Combination of Cladribine, Low Dose Cytarabine and Sorafenib Alternating With Decitabine in Pediatric Relapsed and Refractory Acute Leukemias (NCT06474663) | M.D. Anderson Cancer Center | 2025-07-31 |
| A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2) (NCT07073547) | AstraZeneca | 2025-07-31 |
| Evaluation of Safety, Tolerance, and Efficacy of Allogeneic LB-DTK-COV19 in Severe Coronavirus Disease 2019 Patients (NCT07709637) | LucasBio | 2025-07-31 |
| Study of SYN608 for the Treatment of Advanced or Metastatic Solid Tumors (NCT07088588) | Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd | 2025-07-31 |
| Phase 1 Study of HS-20093 Combinations in Patients With Extensive Stage Small Cell Lung Cancer (NCT07063407) | Shanghai Hansoh Biomedical Co., Ltd | 2025-07-31 |
| AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors (NCT07094113) | Amgen | 2025-07-31 |
| Safety and Efficacy of Canagliflozin in Patients With Metastatic High Microsatellite Instability (MSI-H) Colorectal Cancer (NCT07076823) | West China Hospital | 2025-07-31 |
| A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia (NCT06721013) | Eli Lilly and Company | 2025-07-30 |
| Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06) (NCT06780111) | Merck Sharp & Dohme LLC | 2025-07-30 |
| A Study of BL-M09D1 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer and Other Solid Tumors (NCT07056556) | Sichuan Baili Pharmaceutical Co., Ltd. | 2025-07-30 |
| Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8) (NCT07079475) | Dizal (Jiangsu) Pharmaceutical Co., Ltd. | 2025-07-30 |
| A Phase I Study of SPGL008 in Subjects With Advanced Malignant Tumors (NCT07038005) | Shenyang Sunshine Pharmaceutical Co., LTD. | 2025-07-30 |
| A Clinical Study of Multi-target Hi-TCR-T Cells in the Treatment of Advanced Hepatocellular Carcinoma (NCT06902389) | Eastern Hepatobiliary Surgery Hospital | 2025-07-30 |
| Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors (NCT07021066) | SystImmune Inc. | 2025-07-30 |
| Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma (NCT06860594) | National Cancer Institute (NCI) | 2025-07-30 |
| First-in-Human Clinical Trial of STUP-001, an In Vivo Direct Cell Conversion Gene Therapy for AIS-A/B Chronic Spinal Cord Injury (NCT06922890) | Yonsei University | 2025-07-30 |
| A Phase 1 Study of AOH1996 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (NCT06763341) | City of Hope Medical Center | 2025-07-30 |
| TQB2922 and TAS-102 Tablets for Injection With or Without Bevacizumab in Chemotherapy-failed RAS/BRAF Wild-type Advanced Colorectal Cancer (NCT07044908) | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | 2025-07-30 |
| Glofitamab With Obinutuzumab Pre-treatment for the Treatment of Central Nervous System Lymphoma (NCT06922604) | City of Hope Medical Center | 2025-07-30 |
| A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma (NCT07124936) | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | 2025-07-30 |
| Safety and Efficacy of RN1201 Injection as First-Line Treatment for Newly Diagnosed Multiple Myeloma (NCT07652138) | The First Affiliated Hospital of Soochow University | 2025-07-30 |
| Study of BHV-1400 in IgA Nephropathy (NCT07054684) | Biohaven Therapeutics Ltd. | 2025-07-30 |
| A Food Effect Study of LY03020 in Healthy Subjects (NCT07292233) | Luye Pharma Group Ltd. | 2025-07-30 |
| CUE-102 in Recurrent Glioblastoma (NCT06917885) | David Reardon, MD | 2025-07-30 |
| A Study to Investigate Safety and Preliminary Efficacy of SOA101 in Adult Subjects With Advanced Solid Tumors (NCT07055594) | Shine-On Biomedical Co., Ltd. | 2025-07-30 |
| Safety and Tolerability of CVHNLC Plus Pembrolizumab in Patients With Squamous Non Small-Cell Lung Cancer (sqNSCLC) (NCT07073183) | CureVac | 2025-07-30 |
| Safety, Tolerability and Pharmacokinetics of EM-I-2024 (NCT07584668) | National Medical Research Radiological Centre of the Ministry of Health of Russia | 2025-07-30 |
| An Individual Patient, Open Label Study to Use ACER-001 to Treat Combined D,L-2 Hydroxyglutaric Aciduria (C-2HGA) (NCT07125066) | Jerry Vockley, MD, PhD | 2025-07-30 |
| Study of S-892216 Long-acting Injectable (LAI) in Healthy Adult Participants (NCT07093580) | Shionogi | 2025-07-29 |
| A Study of Valemetostat Tosylate (DS-3201b) With Atezolizumab and Bevacizumab in HCC (NCT06294548) | University of Alabama at Birmingham | 2025-07-29 |
| CD19 Chimeric Antigen Receptor (CAR) T Cells in Adults With Relapsed/Refractory CD19 Positive Acute Lymphoblastic Leukemia (NCT07361029) | King Faisal Specialist Hospital & Research Center | 2025-07-29 |
| Comparative Acute Effects of R-MDMA and S-MDMA in Healthy Participants (NCT06905652) | University Hospital, Basel, Switzerland | 2025-07-29 |
| A Study to Assess Safety, Tolerability, and Pharmacokinetics of Ascending Concentrations of Topical Ocular BL1332 in Healthy Volunteers (NCT06978244) | Bausch & Lomb Incorporated | 2025-07-29 |
| A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors (NCT07115043) | AstraZeneca | 2025-07-29 |
| A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of the GSK 4-component Strep A Vaccine With Aluminum Hydroxide (Alum) or AS37 in Healthy Young Adults (NCT07085702) | GlaxoSmithKline | 2025-07-29 |
| A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations (NCT07038369) | Atavistik Bio, Inc | 2025-07-29 |
| External Beam Radiation Therapy and Brachytherapy With Chemotherapy and Immunotherapy for the Treatment of Stage IVB Cervical Cancer (NCT06543576) | Jonsson Comprehensive Cancer Center | 2025-07-29 |
| A Study to Test How Well BI 3000202 is Tolerated by People With Type 1 Interferonopathies (NCT06878365) | Boehringer Ingelheim | 2025-07-29 |
| A Study Assessing Brain Activity, Safety, Tolerability, and Pharmacokinetics Following Multiple Doses of MLS101 (Psilocybin) in Healthy Volunteers (NCT07050368) | MycoMedica Life Sciences PBC | 2025-07-28 |
| A Study to Evaluate Safety , Efficacy and Pharmacokinetics of WJ01024 Tablets Combined With Ruxolitinib in Patients With Myelofibrosis (NCT06909136) | Suzhou Junjing BioSciences Co., Ltd. | 2025-07-28 |
| Testing the Potential Metabolic Effect of the Human Gut Bacterial Peptide, RUCILP, in Healthy Men (NCT06923839) | Oluf Pedersen | 2025-07-28 |
| A Study of LY4175408 in Participants With Advanced Cancer (NCT07046923) | Eli Lilly and Company | 2025-07-28 |
| EAST-1 (ERAP-inhibition in Axial Spondyloarthritis Trial - 1) (NCT07047703) | Grey Wolf Therapeutics | 2025-07-28 |
| Effect of Sublingual Formulation of Dexmedetomidine Hydrochloride (HCl) (BXCL501) - Outpatient Study (NCT06335407) | Pharmacotherapies for Alcohol and Substance Use Disorders Alliance | 2025-07-28 |
| Safety and Efficacy of Lyophilized Fecal Microbiota Transplantation Via Capsules for Intestinal Multidrug-resistant Bacteria Decolonization (NCT07106580) | University of Rijeka | 2025-07-28 |
| ERAS-801 for the Treatment of Resectable and Progressive or Recurrent or Elderly Newly Diagnosed IDH Wildtype Grade IV Glioblastoma or Gliosarcoma With an EGFR Amplification or Mutation, ERAS801-SARG Trial (NCT07089641) | Jonsson Comprehensive Cancer Center | 2025-07-28 |
| Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma (NCT06348108) | Alfred Chung, MD | 2025-07-28 |
| Phase I/II Study of SCTB39G in Advanced Solid Tumours (NCT07077252) | Sinocelltech Ltd. | 2025-07-28 |
| Study to Assess the Safety, Tolerability, and Pharmacokinetics of INCB000631 When Administered Orally to Healthy Adult Participants (NCT07039929) | Incyte Corporation | 2025-07-28 |
| Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours. (NCT07148128) | Auricula Biosciences Inc. | 2025-07-28 |
| A Study to Investigate the Effect of Capivasertib on the Pharmacokinetics of Oral Rosuvastatin in Healthy Participants (NCT07088913) | AstraZeneca | 2025-07-28 |
| Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant (NCT06129734) | Benjamin Tomlinson | 2025-07-28 |
| A Study in Healthy People to Compare How 2 Different Formulations of Survodutide Are Taken up in the Body (NCT07071974) | Boehringer Ingelheim | 2025-07-28 |
| A Study to Investigate the Efficacy and Safety of Volrustomig ± Casdatifan vs Nivolumab + Ipilimumab as 1L Treatment for Advanced ccRCC (NCT07000149) | AstraZeneca | 2025-07-28 |
| A Trial of a Gorilla Adenovirus Vectored Networked Epitopes Vaccine, Administered to Healthy Adults Living Without and With HIV. (NCT06617091) | International AIDS Vaccine Initiative | 2025-07-28 |
| Novel Allogenic CD19-targeting CAR-γδT Cell Therapy (QH103E) in r/r NHL (NCT06838832) | Chinese PLA General Hospital | 2025-07-27 |
| SDTM001 Injection as Adjuvant Therapy for NSCLC Patients After Radical Surgical Resection (NCT07096882) | Cytocraft Biopharmaceutical Co., Ltd. | 2025-07-26 |
| ACTengine® IMA203 Combined With mRNA-4203 (NCT06946225) | Immatics US, Inc. | 2025-07-25 |
| A Study of LY3549492 in Chinese Participants With Type 2 Diabetes Mellitus (NCT07073170) | Eli Lilly and Company | 2025-07-25 |
| Liposomal Iron Versus Ferrous Iron Supplementation for Early Prophylaxis of Iron Deficiency Anemia in Preterm Neonates (NCT07667205) | Ain Shams University | 2025-07-25 |
| A First-in-Human Phase 1 Single-Ascending Dose Study of ABCL575 in Healthy Participants (NCT07108894) | AbCellera Biologics Inc. | 2025-07-25 |
| A Proof of Concept, Phase 1 Study of CGB-600 for the Topical Treatment of Non-Segmented Facial Vitiligo (NCT07357870) | CAGE Bio Inc. | 2025-07-25 |
| A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors (NCT07066657) | ArriVent BioPharma, Inc. | 2025-07-25 |
| A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors (NCT07094204) | Astellas Pharma Inc | 2025-07-25 |
| Peds CHAMP1ON - Hematopoietic Stem Cell And Monoclonal Antibody PD-1 Blockade for RecurreNt Pediatric High-Grade Glioma (NCT07031765) | University of Florida | 2025-07-25 |
| Effect of an Experimental Cannabidiol Gel on Tooth Sensitivity (NCT07027566) | Universidade Federal do Para | 2025-07-25 |
| a Safety, Tolerability, and Pharmacokinetic Trial of Multiple Subcutaneous Injections of B1344 Injection in Patients With Nonalcoholic Fatty Liver Disease（NAFLD） (NCT07128797) | Tasly Biopharmaceuticals Co., Ltd. | 2025-07-24 |
| EP102 Safety and Efficacy in METTL3 Modulation in Advanced Solid Tumors (NCT07163325) | Epics Therapeutics | 2025-07-24 |
| A Study of Dara-RVd and Teclistamab-RVd in People With Multiple Myeloma (NCT07099391) | Memorial Sloan Kettering Cancer Center | 2025-07-24 |
| A Study of LY4088044 in Healthy Participants (NCT07090785) | Eli Lilly and Company | 2025-07-24 |
| Phase I/II Clinical Study of SHR-1501 Combined With Adbelizumab in Patients With Malignant Tumors (NCT07073534) | Shanghai Hengrui Pharmaceutical Co., Ltd. | 2025-07-24 |
| Pharmacokinetics of Zelquistinel in Fasted or Fed State (NCT07099989) | Syndeio Biosciences, Inc | 2025-07-24 |
| A Study Evaluating How Moderate Liver Impairment Affects the Absorption, Distribution, Metabolism, and Elimination of Sevabertinib After a Single Oral Dose (NCT07102095) | Bayer | 2025-07-24 |
| A Clinical Study of MK-8294 in Participants With Advanced Solid Tumors (MK-8294-001) (NCT07030712) | Merck Sharp & Dohme LLC | 2025-07-23 |
| A Ketamine-assisted Group Therapy Intervention for Spanish-speaking Adults With Depression (NCT06597695) | Juliana Zambrano, MD, MPH | 2025-07-23 |
| Safety, Tolerability, and Pharmacokinetics of Multiple Dose Combinations of SION-451 and Complementary Modulators SION-2222 and SION-109 in Healthy Participants. (NCT07035990) | Sionna Therapeutics Inc. | 2025-07-23 |
| A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM) (NCT06953960) | AbbVie | 2025-07-23 |
| First-in-Human PfSPZ-LARC2 Vaccination/CHMI (NCT06735209) | National Institute of Allergy and Infectious Diseases (NIAID) | 2025-07-23 |
| A Study to Investigate the Safety, Tolerability, and Efficacy of SAR446268, an Adeno-associated Viral Vector-mediated Gene Therapy in Participants Aged 10 to 55 Years of Age With Non-congenital Myotonic Dystrophy Type 1 (NCT06844214) | Sanofi | 2025-07-23 |
| Multi-modular Chimeric Antigen Receptor T Cells tarGeting B7-H3 in Children, Teenage & Young Adult Sarcoma (NCT07751380) | University College, London | 2025-07-23 |
| A Study to Investigate the Pharmacokinetics and Safety of Remibrutinib in Participants With Severe Renal Impairment Compared to Matched Healthy Participants. (NCT07032272) | Novartis Pharmaceuticals | 2025-07-23 |
| A Clinical Trial to Assess PVX7 Immunotherapy Regimens in Advanced Cervical Cancer Patients (NCT06315257) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2025-07-23 |
| A Study of mRNA Vaccines AK154 Monotherapy or in Combination With AK104/AK112,and Sequential mFOLFIRINOX in Surgically Resected PDAC (NCT06913218) | Akeso | 2025-07-22 |
| A Study to Evaluate EDG-7500 in People With Renal Impairment (NCT07034768) | Edgewise Therapeutics, Inc. | 2025-07-22 |
| A Study of HS-10504 in Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC) (NCT06461156) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2025-07-22 |
| A Study to Learn About How a New Pneumococcal Vaccine Works in Adults (NCT07086677) | Pfizer | 2025-07-22 |
| NEoadjuvant Chemotherapy and Immunotherapy for a Selected Group of Inoperable Pleural Mesothelioma Patients (NECIM): a Feasibility Study (NCT07121374) | University Hospital, Antwerp | 2025-07-22 |
| A Study to Investigate the Safety and Biodistribution of a Single Intrathecal (IT) Injection of INS1201 in Ambulatory Males With Duchenne Muscular Dystrophy (DMD) (NCT06817382) | Insmed Gene Therapy LLC | 2025-07-22 |
| Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors (NCT06960395) | Vir Biotechnology, Inc. | 2025-07-22 |
| A Study Investigating the Change in Metabolism Phenotype in Paediatric, Adolescent & Young Adults With Hodgkin or Non-Hodgkin Lymphoma. (NCT06383338) | Murdoch Childrens Research Institute | 2025-07-22 |
| A Study of PARG Inhibitor FORX-428 in Patients With Advanced Solid Tumors. (NCT07356453) | FoRx Therapeutics AG | 2025-07-22 |
| A Phase I/II Study of HY05350 in Mesothelin(MSLN)-Positive Advanced Solid Tumors (NCT07083323) | Sichuan Huiyu Pharmaceutical Co., Ltd | 2025-07-22 |
| A Clinical Study of SHR-4506 Injection in Patients With Malignant Tumors (NCT07068932) | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 2025-07-22 |